Comparison of Efficacy Between 100% Platelet-rich Plasma and 100% Serum Eye Drops in Dry Eye Disease

Last updated: October 18, 2023
Sponsor: Mahidol University
Overall Status: Completed

Phase

3

Condition

Sjogren's Syndrome

Dry Eyes

Eyelid Inflammation

Treatment

100% Autologous platelet rich plasma

100% Autologous serum

Clinical Study ID

NCT04683796
1996
  • Ages 18-75
  • All Genders

Study Summary

Dry eye disease (DED) is a common eye problem, affecting 5% to 50% of the world population. Although the disease is not fatal, it substantially reduces quality of life and creates a high economic burden as high as over 50 billion from a societal perspective. Several biological tear substitutes (e.g., autologous serum (AS), autologous platelet rich plasma (APRP), and autologous platelet lysate (APL)) could effectively improve dry eyes, especially in patients with moderate to severe DED.. However, evidence on their comparative efficacy is controversial. The objective of the study is to compare the efficacy of 100% APRP with 100% AS eye drops in patients with moderate to severe DED.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged 18 to less than 75 years.
  • Have OSDI scores ≥ 23 or Oxford staining grade ≥ 2.
  • Do not have following conditions: Uncontrolled systemic diseases, active infection, advanced cancer. Pregnant and nursingwomen. • Have not recently used the following medications/interventions/surgery:Anticoagulants or anti-platelets. Topical undiluted blood products within 3 months. Punctalplug or contact lenses. Ocular surgery within 6 months.
  • Do not have active ocular infection/inflammation, abnormal eyelid function or severemeibomian gland dysfunction (MGD stage 4).
  • Have no contraindication for blood donations: Positive human immunodeficiency virus, hepatitis B or C, or syphilis. Anemia (Hb < 11 g/dL)or platelet concentration < 150,000/ml.
  • Being able to stop current dry eye treatment for 48 hours before staring trialintervention
  • Willing to comply with the 4-week study protocol and provide informed consent.

Exclusion

Exclusion Criteria:

• None

Study Design

Total Participants: 96
Treatment Group(s): 2
Primary Treatment: 100% Autologous platelet rich plasma
Phase: 3
Study Start date:
February 01, 2021
Estimated Completion Date:
March 30, 2023

Study Description

The study is a single-center, double-blinded randomized, parallel, non-inferiority trial. Patients will be recruited from out-patient clinic, Department of Ophthalmology, Ramathibodi Hospital, Bangkok and will be randomized to receive either 100% APRP or 100% AS eye drops (1:1 ratio) for 4 weeks. The primary outcomes include ocular surface disease index (OSDI) and ocular surface staining evaluated using the Oxford scale. Secondary outcomes are fluorescein break-up time (FBUT), Schirmer's I test (ST I), meibomian gland parameters and adverse events.

Connect with a study center

  • Ophthalmology Department, Ramathibodi Hospital

    Ratchathewi, Bangkok 10400
    Thailand

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.